Investment analysis, share recommendations, and market insights.
Just when the data drops in the US were telling us that inflation was falling, rates were about to be cut and the Fed had engineered a soft landing, along came a weaker-than-expected jobs report that has led to recession fears. So, should you be afraid?
In this article, we look at how our income and growth portfolios have performed so far this year.
For our “HOT” stock today, Raymond Chan, Head of Asian Desk at Morgans explains why Morgans considers Resmed (RMD) to be an ADD to an investment portfolio.
Here are two situations where the odds might be on the side of the speculators! But always remember the risk.
It’s an interesting exercise to look at sectors dominated by a stock heavyweight, and search for value in peer stocks not attracting passive capital. The A-REIT sector is a good place to start. Here are two small-cap A-REITs to consider.
In our “HOT” stock column, Michael Gable, managing director of Fairmont Equities, explains why he’s still a buyer of PME for his clients.
In this article I argue the great Aussie stocks in the top 20 list — my Heaven Eleven group — have spiked incredibly in a year but it might be time to look at the other 189 stocks in the S&P/ASX 200 Index.
I’m a great believer in backing track record, so there’s no argument from me when it comes to Macquarie. It is, and remains, a core portfolio stock. The question however is where it sits in the current market: is this a point to acquire more, ease back a touch and take a profit on a small portion, or just sit back?
In our HOT stock column today, Raymond Chan, Head of Asian Desk, explains why Morgans maintains its ADD rating for Mineral Resources Ltd (MIN).
The ASX has a burgeoning life sciences cohort doing great work in a range of major diseases. Here are four interesting cancer fighters.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.